
A modified form of cannabinol (CBN) protected dopamine-producing nerve cells from death in a laboratory model of Parkinson’s disease. Called CS-11, the compound showed the strongest neuroprotective activity among the compounds tested, with an EC₅₀ of 100 nanomolar.
Researchers studied cannabinoid derivatives designed to disrupt the interaction between Keap1 and Nrf2—a pathway that controls cells’ antioxidant defenses. CS-11 increased protective gene activity and restored levels of tyrosine hydroxylase, an enzyme needed to produce dopamine.
Published in ACS Medicinal Chemistry Letters, these laboratory and computational findings identify a promising CBN-derived candidate for Parkinson’s drug development. The research points to strengthening cells’ own protective defenses as a strategy for preserving vulnerable dopamine-producing neurons.
“Oxidative stress and xenobiotic exposure disrupt redox homeostasis and contribute to neurodegenerative disease progression. The Keap1-Nrf2-ARE pathway is a key antioxidant defense mechanism, in which Nrf2 activates cytoprotective gene expression.
Because disrupting the Keap1-Nrf2 interaction can enhance antioxidant responses, we assessed modified Cannabis sativa cannabinoids bearing C- and O-β-d-glucosides as potential Keap1 inhibitors.
Building on our earlier fractionation and derivatization work, these compounds were evaluated for binding to the Keap1 BTB and KDC domains and for activation of Nrf2-mediated responses using in vitro and in silico methods.
In a Parkinson’s disease model, CS-11 (4a) showed the strongest neuroprotective effect, with an EC50 of 100 nM. Treatment significantly increased cytoprotective gene expression, indicating enhanced Nrf2 transcriptional activity. CS-11 (4a) also restored tyrosine hydroxylase levels and protected dopaminergic neurons from cell death. Computational analyses supported its Keap1-targeting activity, identifying CS-11 (4a) as a promising Parkinson’s disease therapeutic candidate.”